Company-wide revenue
Reported revenue in 2021 ¥3.57T Reported revenue in 2025 ¥4.51T
- growth amount
- +¥936.71B
- growth annualized
- +6.0%
- growth total
- +26.2%
Japanese company profile · 4502
Takeda Pharmaceutical Company Limited
In its FY2025 public filing, Takeda Pharmaceutical Company Limited reports Research and development, manufacture, sale and licensing of pharmaceuticals. The page shows business-level revenue and profit where the source disclosures support comparison.
Original Japanese company name: 武田薬品工業株式会社
English company name from the issuer's official source. English company name source
Reported company-wide figures
What does this company do?
What does this company do?
Takeda Pharmaceutical Company Limited's largest reported business by revenue in FY2025 was Research and development, manufacture, sale and licensing of pharmaceuticals.
The business with the highest reported segment profit in FY2025 was Research and development, manufacture, sale and licensing of pharmaceuticals.
FY2025 · fiscal year ended March 2026 View original filing ↗ The source document may be in Japanese.
Business structure
How does it make money?
| Business | Segment revenue | Revenue share | Segment profit (loss) |
|---|---|---|---|
| Research and development, manufacture, sale and licensing of pharmaceuticals | ¥4.51T ↗ | 100.0% | ¥6.22B ↗ |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended March 2026. Revenue and profit are shown only where the filing and data support a comparison.
Original Japanese label
- Research and development, manufacture, sale and licensing of pharmaceuticals
- 医薬品の研究開発、製造、販売およびライセンス供与
- Segment revenue
- セグメント収益
- Segment profit (loss)
- セグメント利益（損失）
Original Japanese label
- Research and development, manufacture, sale and licensing of pharmaceuticals
- 医薬品の研究開発、製造、販売およびライセンス供与
- Segment revenue
- セグメント収益
- Segment profit (loss)
- セグメント利益（損失）
Reported Segment revenue by business over time
Reported Segment revenue by business over time
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Research and development, manufacture, sale and licensing of pharmaceuticals | ¥3.57T | ¥4.03T | ¥4.26T | ¥4.58T | ¥4.51T |
All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.
What is growing?
What is growing?
Business revenue growth
Research and development, manufacture, sale and licensing of pharmaceuticals
Reported revenue in 2021 ¥3.57T Reported revenue in 2025 ¥4.51T
- growth amount
- +¥936.71B
- growth annualized
- +6.0%
- growth total
- +26.2%
View original filing
This describes a reported period; it is not a forecast.
What has changed?
What has changed?
Not disclosed or not safely comparable in the available filings.
Source
Public filing
FY2025 · fiscal year ended March 2026
The source document may be in Japanese.
Filing ID: S100YB5L
View original filing ↗Ask about this company
Ask about this company
The source document may be in Japanese.